Gypenoside LXXV, isolated from Gynostemma pentaphyllum , is one of the deglycosylated shapes of ginsenoside Rb1. Gypenoside LXXV significantly reduces cancer cell viability and displays an anti-cancer effect.

Gypenoside LXXV (1.0-100 μM; for 48 hours) reduces proliferation in a dose-dependent manner[1]. Cell Viability Assay[1]Cell Line: Three cancer cell lines (HeLa (cervical cancer cell line), B16 (melanoma cell line), and MDA-MB231 (human breast cancer cell line) Concentration: 1.0-100 μM Incubation Time: For 48 hours Result: Reduced proliferation in a dose-dependent manner and inhibited almost all cancer cells at 50 μM.

110261-98-8

C42H72O13

785.01

Gypenoside LXXV

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years